Analysts Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Price Target at $7.33

Posted by Geri Gentry on Aug 31st, 2026

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) has received an average rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $7.3333.

NMTC has been the subject of several recent research reports. LADENBURG THALM/SH SH upped their target price on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings downgraded NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. Finally, Maxim Group set a $5.00 price objective on NeuroOne Medical Technologies and gave the company a “buy” rating in a research report on Friday, August 14th.

View Our Latest Analysis on NeuroOne Medical Technologies

NeuroOne Medical Technologies Price Performance

Shares of NMTC opened at $1.77 on Monday. The stock has a market capitalization of $16.12 million, a PE ratio of -1.86 and a beta of 0.61. NeuroOne Medical Technologies has a 12-month low of $1.42 and a 12-month high of $6.96. The business’s fifty day moving average price is $2.28 and its 200 day moving average price is $3.56.

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%.The business had revenue of $1.97 million during the quarter, compared to the consensus estimate of $2.17 million. As a group, research analysts anticipate that NeuroOne Medical Technologies will post -0.39 earnings per share for the current fiscal year.

Insider Transactions at NeuroOne Medical Technologies

In other news, Director Mark Christianson sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total transaction of $31,800.00. Following the completion of the transaction, the director owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. The trade was a 32.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Several hedge funds have recently bought and sold shares of NMTC. Vanguard Group Inc. grew its position in NeuroOne Medical Technologies by 31.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after purchasing an additional 375,639 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of NeuroOne Medical Technologies by 10.2% during the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after buying an additional 70,428 shares during the period. Bard Associates Inc. acquired a new position in shares of NeuroOne Medical Technologies during the second quarter worth approximately $929,000. Essex Investment Management Co. LLC bought a new position in NeuroOne Medical Technologies in the 4th quarter worth approximately $143,000. Finally, Virtu Financial LLC acquired a new stake in NeuroOne Medical Technologies in the 3rd quarter valued at approximately $88,000. 16.07% of the stock is currently owned by institutional investors.

NeuroOne Medical Technologies Company Profile

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.